Silvana Canevari

List of Publications by Year
in descending order

73 papers	1,848 citations	257357 24 h-index	276775 41 g-index
73 all docs	73 docs citations	73 times ranked	4528 citing authors

#	Article	IF	Citations
1	Development of a multiomics database for personalized prognostic forecasting in head and neck cancer: The Big Data to Decide <scp>EU</scp> Project. Head and Neck, 2021, 43, 601-612.	0.9	18
2	Validity of Anti-PSMA ScFvD2B as a Theranostic Tool: A Narrative-Focused Review. Biomedicines, 2021, 9, 1870.	1.4	4
3	Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience. Cells, 2020, 9, 903.	1.8	8
4	Main Barriers and Needs to Support Clinical Cancer Research via Health Informatics. IFMBE Proceedings, 2020, , 174-182.	0.2	0
5	Mining of Self-Organizing Map Gene-Expression Portraits Reveals Prognostic Stratification of HPV-Positive Head and Neck Squamous Cell Carcinoma. Cancers, 2019, 11, 1057.	1.7	25
6	A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes. Oral Oncology, 2019, 90, 94-101.	0.8	12
7	Integration of MRI and MRS approaches to monitor molecular imaging and metabolomic effects of trabectedin on a preclinical ovarian cancer model. NMR in Biomedicine, 2019, 32, e4016.	1.6	7
8	DIPG-46. IDENTIFICATION OF CIRCULATING miRNAs IN DIPG PATIENTS AS PREDICTORS OF RESPONSE TO TARGETED THERAPY AND AS CLASSIFIERS OF CLINICAL OUTCOME. Neuro-Oncology, 2018, 20, i58-i58.	0.6	0
9	The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial–mesenchymal transition, and immune response. Cancer Communications, 2018, 38, 1-14.	3.7	25
10	Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer. Clinical Cancer Research, 2018, 24, 5098-5111.	3.2	65
11	Simultaneous E-cadherin and PLEKHA7 expression negatively affects E-cadherin/EGFR mediated ovarian cancer cell growth. Journal of Experimental and Clinical Cancer Research, 2018, 37, 146.	3.5	25
12	Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells. MAbs, 2018, 10, 1084-1097.	2.6	17
13	Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial. Oral Oncology, 2018, 82, 144-151.	0.8	13
14	Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling. Cancer Research, 2017, 77, 1127-1141.	0.4	58
15	Gene Expression Signatures for Head and Neck Cancer Patient Stratification: Are Results Ready for Clinical Application?. Current Treatment Options in Oncology, 2017, 18, 32.	1.3	40
16	β–Catenin in desmoid–type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression. Molecular Oncology, 2017, 11, 1495-1507.	2.1	28
17	Perfusion of isolated rat kidney with Mesenchymal Stromal Cells/Extracellular Vesicles prevents ischaemic injury. Journal of Cellular and Molecular Medicine, 2017, 21, 3381-3393.	1.6	102
18	Integrative miRNA-Gene Expression Analysis Enables Refinement of Associated Biology and Prediction of Response to Cetuximab in Head and Neck Squamous Cell Cancer. Genes, 2017, 8, 35.	1.0	27

#	Article	IF	Citations
19	Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?. Disease Markers, 2017, 2017, 1-9.	0.6	4
20	Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging. Oncotarget, 2017, 8, 10919-10930.	0.8	17
21	New transcriptional-based insights into the pathogenesis of desmoplastic small round cell tumors (DSRCTs). Oncotarget, 2017, 8, 32492-32504.	0.8	14
22	Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation and *in vivo* tumor growth in a highly tumorigenic ovarian cancer model. Oncotarget, 2017, 8, 55022-55038.	0.8	11
23	miRNA-based signature for predicting epithelial ovarian cancer recurrence. Translational Cancer Research, 2017, 6, S232-S234.	0.4	1
24	Whole-exome sequencing in radically resected gastric cancer (GC): Analysis of patients (pts) with poor prognostic factors from the Italian Trial of Adjuvant Chemotherapy Adenocarcinoma (ITACA-S) trial.. Journal of Clinical Oncology, 2017, 35, 64-64.	0.8	0
25	Choline Metabolism Alteration: A Focus on Ovarian Cancer. Frontiers in Oncology, 2016, 6, 153.	1.3	40
26	In vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian Cancer. Frontiers in Oncology, 2016, 6, 164.	1.3	8
27	Targeting folate receptor alpha for cancer treatment. Oncotarget, 2016, 7, 52553-52574.	0.8	308
28	Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. Lancet Oncology, The, 2016, 17, 1137-1146.	5.1	97
29	Applicability of Under Vacuum Fresh Tissue Sealing and Cooling to Omics Analysis of Tumor Tissues. Biopreservation and Biobanking, 2016, 14, 480-490.	0.5	10
30	Whole exome sequencing and single nucleotide polymorphism array analyses to identify germline alterations in genes associated with testosterone metabolism in a patient with androgen insensitivity syndrome and early-onset colorectal cancer. Chinese Journal of Cancer, 2016, 35, 51.	4.9	3
31	Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab. Clinical Cancer Research, 2016, 22, 3961-3970.	3.2	65
32	Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma. Clinical Genitourinary Cancer, 2016, 14, e81-e90.	0.9	4
33	Tumor microenvironment in diffuse large B-cell lymphoma: Matrixmetalloproteinases activation is mediated by osteopontin overexpression. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 483-489.	1.9	29
34	Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC. Oncotarget, 2016, 7, 72654-72661.	0.8	15
35	Axl in ovarian cancer: a step forward for clinical breakthrough?. Oncotarget, 2016, 7, 80105-80106.	0.8	0
36	Interleukin 21 Controls mRNA and MicroRNA Expression in CD40-Activated Chronic Lymphocytic Leukemia Cells. PLoS ONE, 2015, 10, e0134706.	1.1	16

#	Article	IF	Citations
37	ITOC2 â€" 038. Role of exosomes in immune suppression. European Journal of Cancer, 2015, 51, S13.	1.3	3
38	T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. Clinical and Experimental Metastasis, 2015, 32, 29-38.	1.7	51
39	Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen. Immunology Letters, 2015, 168, 105-110.	1.1	11
40	Targeting FR-expressing cells in ovarian cancer with Fab-functionalized nanoparticles: a full study to provide the proof of principle from in vitro to in vivo. Nanoscale, 2015, 7, 2336-2351.	2.8	27
41	Inhibition of Phosphatidylcholine-Specific Phospholipase C Interferes with Proliferation and Survival of Tumor Initiating Cells in Squamous Cell Carcinoma. PLoS ONE, 2015, 10, e0136120.	1.1	20
42	A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. Oncotarget, 2015, 6, 5118-5133.	0.8	37
43	Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data. Oncotarget, 2015, 6, 9627-9642.	0.8	103
44	Global metabolic profile identifies choline kinase alpha as a key regulator of glutathione-dependent antioxidant cell defense in ovarian carcinoma. Oncotarget, 2015, 6, 11216-11230.	0.8	20
45	Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration. Oncotarget, 2015, 6, 28173-28182.	0.8	34
46	Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome. Oncotarget, 2015, 6, 30859-30875.	0.8	32
47	Detecting characteristics of nodal invasion in advanced squamocellular oral cavity cancer through a gene expression profile on primary tumor.. Journal of Clinical Oncology, 2015, 33, e17069-e17069.	0.8	0
48	Molecular signature of patients with pre-treated urothelial carcinoma (UC) achieving extreme responses to pazopanib (PZP) salvage therapy.. Journal of Clinical Oncology, 2015, 33, e15514-e15514.	0.8	0
49	Upregulation of RAS pathway to predict the risk of distant metastases in HPV + oropharynx cancer.. Journal of Clinical Oncology, 2015, 33, e17073-e17073.	0.8	0
50	Abstract 3268: Gene expression associated to relapsing disease in Wilms tumor indicates a more differentiated phenotype unveiling a distinct transformation process for patients with a higher risk of relapse. , 2015, , .		0
51	Abstract 1086: CTNNB1-mutated desmoid tumors have different gene expression patterns compared to wild-type ones. , 2015, , .		0
52	Introductory Remarks for the Diagnostic and Therapeutic Applications of Monoclonal Antibodies and Various Formats. , 2014, , 83-90.		0
53	Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer. EMBO Molecular Medicine, 2014, 6, 295-295.	3.3	3
54	Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression. Cancer Research, 2014, 74, 130-140.	0.4	27

#	Article	IF	Citations
55	Identification of a gene expression driven progression pathway in myxoid liposarcoma. Oncotarget, 2014, 5, 5965-5977.	0.8	16
56	An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response. BMC Genomics, 2013, 14, 508.	1.2	21
57	Feasibility of circulating miRNA microarray analysis from archival plasma samples. Analytical Biochemistry, 2013, 437, 123-125.	1.1	23
58	Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer. EMBO Molecular Medicine, 2013, 5, 707-722.	3.3	49
59	Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors. Future Oncology, 2013, 9, 527-539.	1.1	35
60	Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors. International Journal of Cancer, 2013, 132, 2597-2605.	2.3	39
61	Bevacizumab treatment and quality of life in advanced ovarian cancer. Future Oncology, 2013, 9, 951-954.	1.1	2
62	Clinicopathological Impact of ABCC1/MRP1 and ABCC4/MRP4 in Epithelial Ovarian Carcinoma. BioMed Research International, 2013, 2013, 1-7.	0.9	43
63	Choline Metabolic Profiling by Magnetic Resonance Spectroscopy. Methods in Molecular Biology, 2013, 1049, 255-270.	0.4	9
64	Abstract A89: Loss of HLA molecules as melanoma resistance mechanism in immune checkpoint blockade therapy.. , 2013, , .		1
65	Identification of a gene expression profile associated with progression-free survival (PFS) in relapsed or metastatic (RM) head and neck squamous cell cancer (HNSCC) patients (pts) treated with first-line cetuximab and platinum therapy.. Journal of Clinical Oncology, 2013, 31, 6027-6027.	0.8	2
66	Increased Sensitivity to Chemotherapy Induced by CpG-ODN Treatment Is Mediated by microRNA Modulation. PLoS ONE, 2013, 8, e58849.	1.1	21
67	Measuring MicroRNA Expression Levels in Oncology: from Samples to Data Analysis. Critical Reviews in Oncogenesis, 2013, 18, 273-287.	0.2	21
68	Abstract 324: Pantethine, a new therapeutic approach against ovarian cancer.. , 2013, , .		0
69	A loss of microRNA expression as a characterization of synchronous peritoneal secondary localizations of epithelial ovarian cancer as compared to primary tumors.. Journal of Clinical Oncology, 2013, 31, 11037-11037.	0.8	0
70	Abstract A76: EGFR activation signaling cascade leads to phosphorylation on serine 732 of FAK and mitosis in a subset of epithelial ovarian cancer. , 2013, , .		0
71	Characterisation of $in vivo$ ovarian cancer models by quantitative ^{1}H magnetic resonance spectroscopy and diffusion€weighted imaging. NMR in Biomedicine, 2012, 25, 632-642.	1.6	30
72	Comparison of Microarray Platforms for Measuring Differential MicroRNA Expression in Paired Normal/Cancer Colon Tissues. PLoS ONE, 2012, 7, e45105.	1.1	52

#	ARTICLE	IF	CITATIONS
73	Abstract 226: The focal adhesion kinase is phosphorylated on serine732 by a Growth factor-dependent pathway and contributes to the proliferation of tumor cells. , 2012, , .		0